

Standing Group of Experts on Lumpy Skin Disease in Europe

under the GF-TADs umbrella

Fifth meeting (SGE LSD5)
Budva, Montenegro, 19-20 October 2017

Report by AUSTRIA

Dr. Johann Damoser

LSD epidemiology – evolution since the SG4

UNCHANGED



Control measures applied

ENHANCED PASSIVE SURVEILLANCE:

In depth investigations of animals where LSD could not be ruled out clinically, Equipment necessary to take appropriate skin samples delivered to all districts,

at present 12 animals all over Austria tested

All results negative



Vaccination plan for 2018

Ongoing passive surveillance

If LSD comes closer than 100 km:

- additional active surveillance (28 units, 5% prevalence, 95% confidence) if closer than 50 km:
 - active surveillance intensified

Start of vaccination of cattle only if virus circulation confirmed within borders of AT

- 20 km-radius: start of vaccination within 7 days, finalised within 30 days
- 150 km-radius: start within 14 days, finalised within 50 days
- Subsequently vaccination of the whole AT cattle population
- Austrian vaccination programme submitted to COM on 07.08.2017
- 500.000 doses of vaccine (MSD / Intervet S.A.) purchased already
- Option for 6.4 Mio doses to complete a 3-year vaccination programme
 in entire Austrian cattle population

Standing Group of Experts on LSD in Europe under the GF-TADs umbrella

Specific challenges met since the LSD4?

Purchase of vaccine

Agreement on further deliveries if needed

Legal act which adresses specifically LSD nearly finalised







• Standing Group of Experts on LSD in Europe under the GF-TADs umbrella